CORY FREEDLAND

Cory Freedland stands as a pivotal Principal at Samsara BioCapital, a distinguished life sciences venture capital firm renowned for its strategic investments in groundbreaking biotechnology companies. In his role, Mr. Freedland is instrumental in shaping the future of medicine by identifying, evaluating, and nurturing early-stage ventures poised to deliver transformative therapeutic solutions. His work at Samsara BioCapital underscores a deep commitment to advancing scientific innovation from concept to clinical reality.

At Samsara BioCapital, Cory Freedland's investment focus spans a broad spectrum of the life sciences sector. He is particularly dedicated to companies developing novel therapeutics, innovative platform technologies, and disruptive medical devices that address significant unmet medical needs. His expertise allows him to delve into complex scientific data and market dynamics, ensuring that Samsara BioCapital invests in opportunities with the highest potential for both scientific breakthrough and patient impact. He actively supports portfolio companies, leveraging his extensive industry knowledge to guide their strategic development and operational growth.

Before joining Samsara BioCapital, Mr. Freedland honed his financial and strategic acumen through diverse experiences within the healthcare and investment sectors. He previously served as an Associate at Third Rock Ventures, another highly respected life sciences venture capital firm, where he gained invaluable insights into company creation and early-stage investment strategies. Prior to his venture capital career, Cory worked as an Analyst in the Healthcare Investment Banking division at Goldman Sachs. This foundational experience provided him with a robust understanding of corporate finance, mergers and acquisitions, and capital markets within the healthcare industry.

Cory Freedland's academic background further solidifies his expertise. He graduated from Harvard University with an AB in Chemistry and Physics, providing him with a strong scientific foundation that is crucial for evaluating complex biotechnological innovations. This blend of scientific rigor and financial expertise positions him as a highly effective investor capable of discerning promising technologies and guiding them towards success. His contributions are vital in Samsara BioCapital's mission to back visionary entrepreneurs and scientists who are developing the next generation of life-saving medicines.